Sodium butyrate alleviates free fatty acid-induced steatosis in primary chicken hepatocytes via the AMPK/PPARα pathway DOI Creative Commons

Jiayi Ding,

Jiuyue Liu,

Jinyan Chen

и другие.

Poultry Science, Год журнала: 2024, Номер 103(4), С. 103482 - 103482

Опубликована: Янв. 25, 2024

Fatty liver hemorrhagic syndrome (FLHS) is a prevalent metabolic disorder observed in egg-laying hens, characterized by fatty deposits and cellular steatosis the liver. Our preliminary investigations have revealed marked decrease concentration of butyric acid FLHS strain laying hens. It has been established that sodium butyrate (NaB) protects against disorders. However, underlying mechanism which modulates hepato-lipid metabolism to great extent remains unexplored. In this study, we constructed an isolated vitro model chicken primary hepatocytes induce hepatic free acids (FFA). results demonstrate treatment with NaB effectively mitigated FFA-induced inhibiting lipid accumulation, downregulating mRNA expression lipo-synthesis-related genes (sterol regulatory element binding transcription factor 1 (SREBF1), acetyl-CoA carboxylase 1(ACC1), synthase (FASN), stearoyl-CoA desaturase (SCD1), X receptor α (LXRα), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR)) (P < 0.05), upregulating protein AMP-activated kinase α1 (AMPKα1), peroxisome proliferator-activated (PPARα), carnitine palmitoyl-transferase 1A (CPT1A) 0.05). Moreover, AMPK PPARα inhibitors (Compound C (Comp C) GW6471, respectively) reversed protective effects blocking AMPK/PPARα pathway, leading droplet accumulation triglyceride (TG) contents hepatocytes. With these findings, can alleviate hepatocyte lipoatrophy injury activating promoting oxidation, reducing synthesis hepatocytes, potentially being able provide new ideas for FLHS.

Язык: Английский

The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: a systematic review and meta-analysis of randomized controlled trials DOI Creative Commons
Vali Musazadeh,

Kimia Assadian,

Fatemeh Rajabi

и другие.

Pharmacological Research, Год журнала: 2024, Номер 208, С. 107398 - 107398

Опубликована: Сен. 4, 2024

Язык: Английский

Процитировано

11

Gut Microbiome Modulation in Hepatocellular Carcinoma: Preventive Role in NAFLD/NASH Progression and Potential Applications in Immunotherapy-Based Strategies DOI Creative Commons
Elisa Monti,

Clara Vianello,

Ilaria Leoni

и другие.

Cells, Год журнала: 2025, Номер 14(2), С. 84 - 84

Опубликована: Янв. 9, 2025

Hepatocellular carcinoma (HCC) is a heterogeneous tumor associated with several risk factors, non-alcoholic fatty liver disease (NAFLD) emerging as an important cause of tumorigenesis. Due to the obesity epidemics, occurrence NAFLD has significantly increased nearly 30% prevalence worldwide. HCC often arises in background chronic (CLD), such nonalcoholic steatohepatitis (NASH) and cirrhosis. Gut microbiome (GM) alterations have been linked progression development, investigations reporting crucial role for gut-liver axis microbial metabolites promoting CLD. Moreover, GM affects homeostasis, energy status, immune microenvironment, influencing response immunotherapy interesting therapeutic implications. In this review, we summarize main changes derived (e.g., short-chain acids bile acids) occurring patients progression, emphasizing their potential early diagnostic biomarkers prognostic tools. We discuss weight loss effects diet-based interventions healthy lifestyles treatment patients, highlighting impact on restoration intestinal barrier structure. also describe encouraging preclinical findings modulation improve functions CLD, boost antitumor probiotic supplementations or anti-hypercholesterolemic drug treatment), ultimately delay HCC. The development safe effective strategies that target holds promise cancer prevention treatment, especially if personalized options will be considered.

Язык: Английский

Процитировано

2

Interactions of non-starch polysaccharides with the gut microbiota and the effect of non-starch polysaccharides with different structures on the metabolism of the gut microbiota: A review DOI
Yujiao Sun, Jun Yao, Rui Gao

и другие.

International Journal of Biological Macromolecules, Год журнала: 2025, Номер 296, С. 139664 - 139664

Опубликована: Янв. 9, 2025

Язык: Английский

Процитировано

2

Effects of Selected Food Additives on the Gut Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) DOI Creative Commons
Sara Jarmakiewicz-Czaja, Aneta Sokal, Rafał Filip

и другие.

Medicina, Год журнала: 2025, Номер 61(2), С. 192 - 192

Опубликована: Янв. 22, 2025

The purpose of this article is to present selected food additives as disruptors normal intestinal homeostasis with a potential impact on the development metabolic dysfunction-associated steatotic liver disease (MASLD). A comprehensive literature search was conducted in three major electronic databases: PubMed, ScienceDirect, and Google Scholar. MASLD prevalent condition that closely related global rise obesity. Its pathogenesis multifactorial, genetic, environmental, factors playing key role. “multiple-hit” hypothesis suggests Western-style diet, rich ultra-processed foods, saturated fats, additives, combined low physical activity, contributes obesity, which promotes lipid accumulation liver. Recent studies underscore role impaired MASLD. Food including preservatives, emulsifiers, sweeteners, affect gut health function. Selected preservatives inhibit pathogenic microorganisms but disrupt microbiota, leading changes permeability dysfunction. Some emulsifiers thickeners can cause inflammation alter microbiome, contributing steatosis. Furthermore, use sweeteners such sucralose aspartame has been linked metabolism microbial composition, turn disorders.

Язык: Английский

Процитировано

2

BefA protein alleviates progression of non-alcoholic fatty liver disease by modulating the AMPK signaling pathway through the gut-liver axis DOI
Jie Luo, Yujie Cai, Chao Jia

и другие.

International Journal of Biological Macromolecules, Год журнала: 2025, Номер 294, С. 139446 - 139446

Опубликована: Янв. 5, 2025

Язык: Английский

Процитировано

1

Linoleic Acid, Mitochondria, Gut Microbiome, and Metabolic Health: A Mechanistic Review DOI Creative Commons

Joseph Mercola

Advances in Redox Research, Год журнала: 2025, Номер unknown, С. 100128 - 100128

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

1

Journey of the Probiotic Bacteria: Survival of the Fittest DOI Creative Commons
Allyson Andrade Mendonça, Walter de Paula Pinto Neto,

Giselle Alves da Paixão

и другие.

Microorganisms, Год журнала: 2022, Номер 11(1), С. 95 - 95

Опубликована: Дек. 30, 2022

This review aims to bring a more general view of the technological and biological challenges regarding production use probiotic bacteria in promoting human health. After brief description current concepts, for at an industrial level are presented from physiology central metabolism ability face main forms stress process. Once produced, these cells processed be commercialized suspension or dried added food matrices. At this stage, maintenance cell viability vitality is paramount quality product. Powder products requires development strategies that ensure integrity components cellular functions allow complete recovery time consumption. Finally, once consumed, must very powerful set physicochemical mechanisms within body, which include enzymes, antibacterial molecules sudden changes pH. Understanding action agents induction tolerance fundamental selection increasingly efficient strains order survive colonization intestinal tract promote desired health benefits.

Язык: Английский

Процитировано

38

Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease DOI Open Access

Alejandra Mijangos-Trejo,

Natalia Nuño‐Lámbarri,

Varenka J. Barbero-Becerra

и другие.

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(19), С. 14918 - 14918

Опубликована: Окт. 5, 2023

Alterations in the gut–liver axis and changes gut microbiome are among risk factors for pathogenesis of non-alcoholic fatty liver disease (NAFLD). These patients show increased bacterial overgrowth small intestine impaired intestinal permeability. Therefore, therapeutic options such as probiotics or prebiotics have been investigated to modulate microbiota composition improve NAFLD. Most vivo vitro probiotic studies focused on reducing hepatic fat accumulation. The beneficial effects NAFLD demonstrated animal models, most widely used microorganisms those Lactobacillus Bifidobacterium genera. In help restore integrity barrier. This narrative review summarizes published evidence likely benefits a option with

Язык: Английский

Процитировано

22

Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD) DOI Open Access
Qin Guo, Yun Li, Xin Dai

и другие.

Nutrients, Год журнала: 2023, Номер 15(17), С. 3722 - 3722

Опубликована: Авг. 25, 2023

Metabolic (dysfunction) associated fatty liver disease (MAFLD) is recognized as the most prevalent chronic globally. However, its pathogenesis remains incompletely understood. Recent advancements in gut-liver axis offer novel insights into development of MAFLD. Polysaccharides, primarily derived from fungal and algal sources, abundantly exist human diet exert beneficial effects on glycometabolism, lipid metabolism, inflammation, immune modulation, oxidative stress, release Numerous studies have demonstrated that these bioactivities polysaccharides are with their prebiotic properties, including ability to modulate gut microbiome profile, maintain barrier integrity, regulate metabolites produced by microbiota such lipopolysaccharide (LPS), short-chain acids (SCFAs), bile (BAs), contribute intestinal homeostasis. This narrative review aims present a comprehensive summary current understanding protective MAFLD through interactions metabolites. Specifically, we highlight potential molecular mechanisms underlying polysaccharides, which may give new avenues for prevention treatment

Язык: Английский

Процитировано

21

Gut microbiota and eye diseases: a bibliometric study and visualization analysis DOI Creative Commons
Xiangyu Fu,

Haishan Tan,

Ling Huang

и другие.

Frontiers in Cellular and Infection Microbiology, Год журнала: 2023, Номер 13

Опубликована: Авг. 9, 2023

Introduction Recently the role of gut microbial dysbiosis in many ocular disorders, including but not limited to uveitis, age-related macular degeneration (AMD), diabetic retinopathy (DR), dry eye, keratitis and orbitopathy is a hot research topic field. Targeting microbiota treat these diseases has become an unstoppable trend. Bibliometric study visualization analysis have essential methods for literature medical We aim depict this area's hotspots future directions by bibliometric software methods. Methods search all related publications from Web Science Core Collection. Then, CiteSpace was applied analyze visualize country distributions, dual-map overlay journals, keyword bursts, co-cited references. VOSviewer employed identify authors, journals display co-occurrence networks. Results A total 284 relevant were identified 2009 2023. The number studies been small first five years grown steadily since 2016. These completed 1,376 authors 41 countries worldwide, with United States lead. Lin P published most papers while Horai R author. top journal are both Investigative Ophthalmology &amp; Visual Science. In network, except microbiota, inflammation becomes highest frequency. Co-citation analyses reveal that involved common immune- inflammation-mediated eye diseases, retinopathy, degeneration, Graves' orbitopathy, microbiomes no longer bacterial populations. Therapeutic strategies target such as probiotics, healthy diet patterns, fecal transplantation, effective critical research. Conclusions conclusion, displays developmental involvement pathogenesis treatment some diseases. It provides overview field's dynamic evolution structural relationships.

Язык: Английский

Процитировано

18